000300364 001__ 300364
000300364 005__ 20250724114201.0
000300364 0247_ $$2doi$$a10.1158/1078-0432.CCR-24-1845
000300364 0247_ $$2pmid$$apmid:40227208
000300364 0247_ $$2ISSN$$a1078-0432
000300364 0247_ $$2ISSN$$a1557-3265
000300364 0247_ $$2altmetric$$aaltmetric:176261484
000300364 037__ $$aDKFZ-2025-00798
000300364 041__ $$aEnglish
000300364 082__ $$a610
000300364 1001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b0$$eFirst author$$udkfz
000300364 245__ $$aA Prospective Study Consortium for the Discovery and Validation of Early Detection Markers for Ovarian Cancer ('PREDICT') - Baseline findings for CA125.
000300364 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2025
000300364 3367_ $$2DRIVER$$aarticle
000300364 3367_ $$2DataCite$$aOutput Types/Journal article
000300364 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1750081718_24753
000300364 3367_ $$2BibTeX$$aARTICLE
000300364 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300364 3367_ $$00$$2EndNote$$aJournal Article
000300364 500__ $$a#EA:C020#LA:C020# / 2025 Jun 13;31(12):2441-2453
000300364 520__ $$aEpithelial ovarian cancer (EOC) is a lethal malignancy. CA125, the 'best' available marker for detecting EOC, has insufficient sensitivity and specificity for earlier-stage disease and is not a meaningful screening tool, motivating the search for further biomarkers. Cancer biomarker discovery is enhanced by 'omics' technologies. Discovery studies for EOC biomarkers should be conducted in pre-diagnosis blood samples from prospective cohorts to maximize likelihood of identifying markers that can detect disease before usual diagnosis and in earlier disease stage, while reducing methodologic biases.Individual cohorts with pre-diagnosis blood samples have insufficient sample size for such studies. thus, we established 'PREDICT' ('Prospective Early Detection Consortium for Ovarian Cancer')-a collaboration of nine prospective studies-to assemble a sufficient number of EOC cases with blood samples collected ≤18 months before diagnosis plus controls. The 457 cases and 1,687 controls have circulating CA125 measured using a clinical assay.The discrimination capacity for single CA125 measurements in samples collected <6 months prior to diagnosis was high (area under the curve (AUC), PREDICT overall=0.92; range across cohorts of non-pregnant individuals=0.89-0.98), and declined with extended time between blood collection and diagnosis. Between-cohort variability in CA125 levels and predictive performance was observed.Ongoing investigations in PREDICT are evaluating the early detection potential of tumor-associated autoantibodies and microRNAs, using CA125 as a benchmark. PREDICT is a well-characterized resource for identifying and validating detection markers for EOC that may then be used in multi-modal screening, as a complement to CA125 and combined with imaging.
000300364 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300364 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300364 7001_ $$0P:(DE-He78)0ee96cf24374ef9b87086e9395880af9$$aCooley, Victoria$$b1$$udkfz
000300364 7001_ $$0P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aMukama, Trasias$$b2
000300364 7001_ $$00000-0003-2419-8536$$aTeras, Lauren R$$b3
000300364 7001_ $$00000-0001-9997-1218$$aPatel, Alpa V$$b4
000300364 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b5
000300364 7001_ $$00000-0003-1493-4288$$aCrous-Bou, Marta$$b6
000300364 7001_ $$00000-0002-2572-6727$$aHarris, Holly R$$b7
000300364 7001_ $$00000-0002-9446-4855$$aLangseth, Hilde$$b8
000300364 7001_ $$00000-0002-5770-1380$$aSurcel, Heljä-Marja$$b9
000300364 7001_ $$00000-0003-1251-0836$$aWentzensen, Nicolas$$b10
000300364 7001_ $$00009-0002-5848-4661$$aTerry, Kathryn$$b11
000300364 7001_ $$00000-0002-4526-2181$$aSasamoto, Naoko$$b12
000300364 7001_ $$00000-0002-6986-7046$$aTworoger, Shelley$$b13
000300364 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b14$$eLast author$$udkfz
000300364 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-24-1845$$n12$$p2441-2453$$tClinical cancer research$$v31$$x1078-0432$$y2025
000300364 8767_ $$8APC600653186$$92025-04-14$$d2025-07-23$$eAPC$$jZahlung erfolgt$$v0.00
000300364 8767_ $$8APC600653186$$92025-04-14$$d2025-07-23$$eOther$$jZahlung erfolgt$$v0.00
000300364 909CO $$ooai:inrepo02.dkfz.de:300364$$pVDB$$pOpenAPC$$popenCost
000300364 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300364 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0ee96cf24374ef9b87086e9395880af9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000300364 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000300364 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000300364 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300364 9141_ $$y2025
000300364 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000300364 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2024-12-27
000300364 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000300364 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000300364 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300364 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300364 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300364 980__ $$ajournal
000300364 980__ $$aVDB
000300364 980__ $$aI:(DE-He78)C020-20160331
000300364 980__ $$aUNRESTRICTED
000300364 980__ $$aAPC